Radnor Capital Management LLC Invests $910,000 in Illumina, Inc. (NASDAQ:ILMN)

Radnor Capital Management LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 6,980 shares of the life sciences company's stock, valued at approximately $910,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock valued at $34,000 after buying an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in Illumina during the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina in the second quarter worth approximately $61,000. Finally, Mizuho Securities Co. Ltd. bought a new position in shares of Illumina in the second quarter valued at approximately $63,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on ILMN shares. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday. Piper Sandler cut their price target on shares of Illumina from $200.00 to $195.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, TD Cowen increased their price target on Illumina from $166.00 to $177.00 and gave the company a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $162.18.

Illumina Price Performance

Shares of ILMN traded up $3.32 during midday trading on Thursday, hitting $155.15. 2,162,717 shares of the company traded hands, compared to its average volume of 2,008,265. The stock has a 50-day moving average of $137.27 and a 200-day moving average of $123.12. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a one year low of $89.00 and a one year high of $156.66. The firm has a market cap of $24.72 billion, a P/E ratio of -15.58 and a beta of 1.13.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. Illumina's revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 3.62 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.